MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2025 International Congress

    Combining Machine Learning and Linear Mixed Models to Estimate Medication Effect in People with Parkinson’s Disease

    A. Castro Mejia, S. Sapienza, L. Pavelka, R. Kruger, J. Klucken (Belvaux, Luxembourg)

    Objective: To estimate medication effect, as the score difference between MDS-UPDRS III in OFF and ON-state, using a minimal set of clinical features. Background: The…
  • 2025 International Congress

    A Study Of Axial Postural Abnormality In Parkinson`s

    V. Rama Raju (Hyderabad, India)

    Objective: APA involves distinct modes plus sequence patterns and proven predictors for every APA remains mystery. The goal is to probe the progress of APA…
  • 2025 International Congress

    A Phase II Randomized, Parallel, Double-blind, Placebo-controlled Study of the Efficacy and Safety of WD-1603 in Subjects with Parkinson’s Disease

    X. Wei, L. Chen, X. Hu, J. Guo, C. Liu, J. Wang (Shanghai, China)

    Objective: To investigate the effectiveness, safety and pharmacokinetics of WD-1603 carbidopa-levodopa controlled-release tablets in subjects with Parkinson's disease. Background: The development of drug products that…
  • 2025 International Congress

    Influence of age at onset on medication profile in patients with Parkinson’s disease: A prospective study from a tertiary care center in India

    VV. Holla, S. Prasad, T. Nagaraj, SGS. Bhat, M. Bhardwaj, DK. Samartha, SS. Nair, P. Mailankody, RR. Mahale, N. Kamble, R. Yadav, PK. Pal (Bengaluru, India)

    Objective: To study the effect of age at onset on the medication profile of various Parkinson's disease (PD) related medications. Background: Multiple factors determine the…
  • 2025 International Congress

    The effect of vortioxetine and mirtazapine on levodopa-induced dyskinesia in a rat model of Parkinson’s disease

    R. Tohge, S. Satoshi, Y. Yakushiji (Osaka, Japan)

    Objective: To investigate the effect of vortioxetine and mirtazapine on levodopa-induced dyskinesia (LID) in a rat model of Parkinson’s disease (PD), we analyzed abnormal involuntary movements (AIMs)…
  • 2025 International Congress

    Long-Term Effect of Opicapone in Parkinson’s Patients Without Motor Complications: 1.5-year EPSILON Study Findings

    J. Ferreira, O. Rascol, F. Stocchi, A. Antonini, H. Brigas, J. Moreira, JF. Rocha, M. Fonseca, J. Holenz, W. Poewe (Lisbon, Portugal)

    Objective: We report motor function, motor complication and tolerability findings of the EPSILON study up to 1.5 years. Background: The 24-week, double-blind, placebo-controlled Phase III…
  • 2025 International Congress

    The Impact of Levodopa on Gait in Parkinson’s Disease: A Quantitative Analysis of Striatal Dopamine Transporter Availability and Lateralization

    YS. Kim, DG. Park, JH. Yoon (Suwon, Republic of Korea)

    Objective: This study aimed to analyze gait changes in Parkinson’s disease (PD) patients before and after levodopa administration, examining correlations between gait parameters and striatal…
  • 2025 International Congress

    Assessing the potential association of rs2298383 in ADORA2A as a predictor of Levodopa-Induced Dyskinesia in Latin American Parkinson’s Disease patients

    HM. Chaparro-Solano, E. Waldo, T. Peixoto-Leal, AF. Schumacher-Schuh, BL. Santos-Lobato, E. Gatto, G. Arboleda, JL. Orozco-Velez, P. Chana-Cuevas, D. Aguillon, M. Rodriguez-Violante, D. Martinez-Ramirez, M. Cornejo-Olivas, A. Vinuela, G. Alvarado, P. Olguín, S. Alcauter, IF. Mata (Cleveland, USA)

    Objective: To analyze the association between ADORA2A-rs2298383 and levodopa induced dyskinesias (LID) in a cohort of Latin American Parkinson’s disease patients. Background: Previous evidence has…
  • 2025 International Congress

    Computer Vision Quantification of Repeated Finger Tapping Demonstrates Aberrant Plasticity in Parkinson’s Disease

    D. Newbold, U. Kang (New York, USA)

    Objective: Test if symptoms of Parkinson's disease (PD) develop through aberrant plasticity. Background: Recent results in 6-hydroxydopamine-lesioned mice show that repeated performance of simple motor…
  • 2025 International Congress

    Mucuna pruriens for FOG in Parkinson’s disease, Do we have a solution for this trivial problem?

    M. Matta, N. Sawal, S. Singh, K. Verma, S. Sharma (Chandigarh, India)

    Objective: To study the effects of Mucuna Pruriens when administered via inhalation route,  to alleviated symptoms of Parkinson's disease most importantly freezing of gait. Background: Mucuna…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley